ArticlePDF Available

Abstract

Anejaculation may occur as a result of neurological disease, iatrogenic injury or be drug induced. We report a case of a 66 year old man who presented with anejaculation following an emergency abdominal aortic aneurysm repair. Due to an elevated prostate specific antigen (PSA) level, the patient underwent a prostate biopsy and was diagnosed with a prostate adenocarcinoma. This was effectively managed using active surveillance, a treatment modality that aims to select only those patients with significant cancer for radical treatment. Despite the possible cause of anejaculation to be iatrogenic, the reader should be aware that prostate cancer may co-exist in, or cause any disorder of the lower urinary tract.
BioMed Central
Page 1 of 2
(page number not for citation purposes)
Cases Journal
Open Access
Case Report
Anejaculation as an atypical presentation of prostate cancer: a case
report
Uwais Mufti, Khurshid R Ghani*, Rateb Samman, Jaspal Virdi and
Bernard Potluri
Address: Department of Urology, Princess Alexandra Hospital, Hamstel Road, Harlow, Essex, CM20 1QX, UK
Email: Uwais Mufti - umufti@googlemail.com; Khurshid R Ghani* - krghani@gmail.com; Rateb Samman - Rateb.Samman@pah.nhs.uk;
Jaspal Virdi - j.virdi@ntlworld.com; Bernard Potluri - potluri@doctors.org.uk
* Corresponding author
Abstract
Anejaculation may occur as a result of neurological disease, iatrogenic injury or be drug induced.
We report a case of a 66 year old man who presented with anejaculation following an emergency
abdominal aortic aneurysm repair. Due to an elevated prostate specific antigen (PSA) level, the
patient underwent a prostate biopsy and was diagnosed with a prostate adenocarcinoma. This was
effectively managed using active surveillance, a treatment modality that aims to select only those
patients with significant cancer for radical treatment. Despite the possible cause of anejaculation to
be iatrogenic, the reader should be aware that prostate cancer may co-exist in, or cause any
disorder of the lower urinary tract.
Background
Anejaculation is defined as the complete absence of ante-
grade or retrograde ejaculation [1]. It is caused by failure
of emission of semen from the prostate and seminal ducts
into the urethra. In the older man, prostate cancer is the
diagnosis of exclusion.
Case presentation
A 66 year old man with a history of hypertension and
ischaemic heart disease was referred by his general practi-
tioner complaining of anejaculation. He had no difficulty
in obtaining erections or orgasm and no history of lower
urinary tract symptoms. Anejaculation coincided with
recent emergency abdominal aortic aneurysm (AAA)
repair. Digital rectal examination (DRE) revealed a mod-
erately enlarged smooth prostate. The prostate specific
antigen (PSA) level was 4.5 ng/l (age related normal range
0–4). The likely cause for anejaculation in this patient was
injury to the sympathetic trunk during AAA repair. The
differential diagnosis was retrograde ejaculation and pros-
tate cancer. Semen analysis of the first voided urine fol-
lowing intercourse excluded retrograde ejaculation. After
informed consent the patient underwent a 14-core tran-
srectal ultrasound (TRUS) guided prostate biopsy. This
revealed a moderately differentiated prostate adenocarci-
noma (Gleason score 6) in only 2 cores (largest focus of
cancer = 2 mm). Following case discussion at a specialist
multi-disciplinary team meeting, the patient was offered
three prostate cancer management options: radical radio-
therapy, brachytherapy or active surveillance. Radical
prostatectomy was not a suitable option due to cardiac
risk factors. The patient opted for active surveillance and
was referred to the Medical Research Council active sur-
veillance study at the Royal Marsden Hospital, London.
Published: 11 August 2008
Cases Journal 2008, 1:81 doi:10.1186/1757-1626-1-81
Received: 22 June 2008
Accepted: 11 August 2008
This article is available from: http://www.casesjournal.com/content/1/1/81
© 2008 Mufti et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cases Journal 2008, 1:81 http://www.casesjournal.com/content/1/1/81
Page 2 of 2
(page number not for citation purposes)
Discussion
Ejaculation is mediated by the sympathetic nervous sys-
tem. Causes of anejaculation include spinal cord injury,
cauda equina lesions, multiple sclerosis, Parkinson's dis-
ease, diabetes mellitus, medication (antihypertensive,
antipsychotic, antidepressants, alcohol) and surgery (aor-
toiliac surgery, retro peritoneal lymph node dissection,
colorectal resection) [1]. The thoracolumbar sympathetic
nerves cause contraction of the smooth muscles of the
prostate, seminal vesicles and vas deferens leading to
emission of seminal fluid into the urethra. These nerves
are prone to injury during AAA repair, especially when
undertaken as an emergency [2]. Aortoiliac surgery can
also lead to damage of the superior hypogastric plexus
and result in erectile dysfunction. In one study, up to 80%
of patients had some form of sexual dysfunction after AAA
surgery [3]. There are no published figures on the rate of
anejaculation only.
Even though a diagnosis of post-AAA repair anejaculation
may have been evident in this case, sexual dysfunction is
also a recognised presentation of prostate cancer. The case
we have presented is the first reported case of prostate can-
cer detected in a patient complaining of anejaculation.
When DRE finding or PSA level is unable to confidently
exclude prostate cancer, patients should be advised of the
risk of prostate cancer. Systematic TRUS guided prostate
biopsy is the gold standard method for diagnosing pros-
tate cancer. As a result of the PSA test, the majority of
modern day prostate cancers are PSA detected cancers.
These patients often have early localised asymptomatic
cancers.
Active surveillance is the most recent management option
in the treatment of localised prostate cancer. It aims to
individualise the management of early low grade
(Gleason score <= 7) prostate cancer by selecting only
those men with significant cancers for curative treatment.
It involves strict monitoring of the PSA level, DRE finding
and histological status by repeat prostate biopsy. Early,
radical treatment is offered to those with evidence of sig-
nificant biochemical or histological progression [4]. This
is in contrast to watchful waiting which for decades has
been associated with less stringent observation criteria
with late, palliative treatment offered to those who
develop symptoms of cancer progression. Early results of
active surveillance have been encouraging. A Royal
Marsden Hospital study found that 80% of 80 patients
recruited to active surveillance continued to be under sur-
veillance after a median of 42 months follow up. 14% of
patients received radical treatment of which all remained
biochemically controlled with no evidence of recurrent
disease. None of the patients in the study developed met-
astatic prostate cancer and there were no deaths from
prostate cancer [5]. A more recent study has examined the
effect of delaying radical treatment in active surveillance
[6]. 38 active surveillance patients were compared to 150
similar patients who underwent immediate surgical inter-
vention. The median interval for delayed surgical inter-
vention was 26.5 months (range 12–73 months). The
investigators found that delaying radical surgery did not
compromise curability.
Active surveillance aims to avoid the morbidity associated
with radical treatment and identify those men with clini-
cally insignificant prostate cancer. Although mature data
from studies on active surveillance is currently limited, it
seems to be an important management option to consider
in men with early low grade prostate cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
UM and KRG were involved in collection of data and
material used during preparation of the paper. UM drafted
an initial version of the paper. KRG was involved in the
inception, drafting and editing of the paper. RS, JSV and
BSP contributed to the initial draft. BSP is the lead clini-
cian involved in the care of the patient and the prime
supervisor of the work. All authors read and approved the
final manuscript.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
References
1. Colpi G, Weidner W, Jungwirth A, Pomerol J, Papp G, Hargreave T,
Dohle G: EAU Guidelines on Disorders of Ejaculation. Euro-
pean Urology 2004, 46:555-558.
2. Jimenez JC, Smith MM, Wilson SE: Sexual dysfunction in men
after open or endovascular repair of abdominal aortic aneu-
rysms. Vascular 2004, 12:186-91.
3. Lee ES, Kor DJ, Kuskowski MA: Incidence of erectile dysfunction
after open abdominal aortic aneurysm repair. Ann Vasc Surg
2000, 14:13-19.
4. Parker C: Active Surveillance: an individualised approach to
early prostate cancer. BJU Int 2003, 92:2-3.
5. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R,
Deamaley D: Early outcomes of active surveillance for local-
ized prostate cancer. BJU Int 2005, 95:956-60.
6. Warlick Christopher, Trock Bruce J, Landis Patricia, Epstein Jonathan
I, Carter H Ballentine: Delayed Versus Immediate Surgical
Intervention and Prostate Cancer Outcome. J National Cancer
Inst 2006, 98:355-357.
Article
Full-text available
Prostate cancer is the fifth most common malignancy worldwide and the second most common in men. It usually metastasizes to bony skeleton, followed by lung, liver, pleura and adrenals. We report a 71 year old male patient who initially presented only with retroperitoneal lymphadenopathy and constitutional symptoms, misleading the diagnosis of retroperitoneal lymphoma. Who later on was discovered to have carcinoma prostate.
Article
Full-text available
Prostate cancer is a common cancer in elderly men and it frequently metastasizes to regional lymph nodes and sometimes to bone. Very rarely in some of the cases it also shows involvement of non-regional lymph nodes like supra-diaphragmatic lymph nodes. In our report, we present a 60-year-old male, initially misdiagnosed as Chronic Obstructive Pulmonary Disease (COPD) with cervical lymph node involvement may be due to infective region or inflammatory pathology, which was later found to have prostatic adenocarcinoma metastatic to supraclavicular lymph nodes. Very less case reports are present which have shown similar presentations. So we would like to highlight that prostatic carcinoma can be present in an atypical form also.
Article
Full-text available
For prostate cancer patients with small, lower-grade tumors, expectant management with delayed surgical intervention (active surveillance) is a rarely used therapeutic option because the opportunity for cure may be lost. We compared outcomes of 38 patients with small, lower-grade prostate cancer in an expectant management program who underwent delayed surgical intervention at a median of 26.5 months (95% confidence interval [CI] = 17 to 32 months; range = 12.0-73.0 months) after diagnosis with 150 similar patients who underwent immediate surgical intervention at a median of 3.0 months (95% CI = 2 to 4 months; range = 1.0-9.0 months) after diagnosis. Noncurable cancer was defined as adverse pathology associated with a less than 75% chance of remaining disease-free for 10 years after surgery. Noncurable cancer was diagnosed in nine (23%) of the 38 patients in the delayed intervention cohort and in 24 (16%) of the 150 men in the immediate intervention group. After adjusting for age and prostate-specific antigen (PSA) density (i.e., PSA value divided by prostate volume) in a Mantel-Haenszel analysis, the risks of noncurable cancer associated with delayed and immediate intervention did not differ statistically significantly (relative risk = 1.08, 95% CI = 0.55 to 2.12; P = .819, two-sided Cochran-Mantel-Haenszel statistic). Age, PSA, and PSA density were all statistically significantly associated with the risk of noncurable cancer (P = .030, .013, and .008, respectively; two-sided chi-square test). Thus, delayed prostate cancer surgery for patients with small, lower-grade prostate cancers does not appear to compromise curability.
Article
The aim of this study is to document the incidence of erectile dysfunction (ED) following open abdominal aortic aneurysm (AAA) repair using a modified International Index of Erectile Function questionnaire (IIEF). An IIEF was mailed to 175 married male patients (mean age +/- SD: 71 +/- 8 years) who had an open AAA repair by one of four board-certified vascular surgeons between 1994 and 1998. The IIEFs were anonymous and asked patients to recall their sexual function before and 3 months after repair. ED was defined in patients with IIEF scores <11 (range 1-30). The overall response rate was 39% (68/175). A comparison of the IIEF results showed that 67/68 patients reported worsening erectile function (p < 0.00001); one respondent reported improved erectile function. On the basis of the IIEF scores, 20/68 patients (29%) were found to have ED and 48/68 patients (71%) had normal function prior to repair. Of the 48 patients with normal function prior to surgery, 83% (40/48) had ED after surgery. ED rates were similar between tube grafts 82% (23/28) and bifurcated grafts 85% (17/20) p = ns. The ED rate after open AAA repair is alarmingly high and prospective follow-up with IIEF will be necessary to better assess true ED rates after conventional open AAA repair.
Article
Few studies have thoroughly investigated the incidence and detailed the degree of sexual disability after aortic aneurysm surgery. Reports prior to 1990 vary greatly in the incidence of postoperative dysfunction mostly because of nonstandardized methods of assessment. In this article, we compare the incidence of reported sexual dysfunction after aortic reconstruction, open and endovascular abdominal aortic aneurysm repair. Pertinent studies on sexual dysfunction following open and endovascular aortic aneurysm repair were identified from a MEDLINE search of English-language publications since 1966. Newer standardized methods of assessment have identified relatively high rates of sexual dysfunction prior to and after intervention. Aortic aneurysm patients have a baseline incidence of sexual dysfunction of approximately 30%, which doubles over the next 7 years. Patients who had open aortic operations reported significantly increased sexual dysfunction during the first postoperative year. Endovascular repair with unilateral internal iliac occlusion results in new sexual dysfunction in approximately 10% of patients, but this increases significantly with bilateral internal iliac occlusion. When compared with open operation, the incidence of sexual dysfunction is lower overall in patients with endovascular aortic aneurysm repairs, which includes those who have internal iliac artery occlusion, but it is increased with bilateral iliac occlusion. Surgeons should be aware of the preoperative prevalence of sexual dysfunction in patients undergoing aortic procedures.
Article
To describe the preliminary clinical outcomes of active surveillance (AS), a new strategy aiming to individualize the management of early prostate cancer by selecting only those men with significant cancers for curative therapy, and illustrate the contrast with a policy of watchful waiting (WW). Eighty men with early prostate cancer began AS at the authors' institution between 1993 and 2002. Eligibility included histologically confirmed prostatic adenocarcinoma, fitness for radical treatment, clinical stage T1/T2, N0/X, M0/X, a prostate specific antigen (PSA) level of < or = 20 ng/mL, and a Gleason score of < or = 7. PSA was measured and a digital rectal examination conducted at 3-6 month intervals. The decision between continued monitoring or radical treatment was informed by the rate of rise of PSA, and was made according to the judgement of each patient and clinician. During the same period, 32 men with localized prostate cancer (any T stage, N0/X, M0/X, any PSA, Gleason score < or = 7) were managed by WW; hormonal treatment was indicated for symptomatic prostate cancer progression. The PSA doubling time (DT) was calculated using linear regression of ln(PSA) against time, using all pretreatment PSA values. At a median follow-up of 42 months, 64 (80%) of the 80 patients on AS remained under observation, 11 (14%) received radical treatment and five (6%) died from other causes. No patient developed evidence of metastatic disease, none started palliative hormone therapy, and there were no deaths from prostate cancer. Of the 11 patients who received radical treatment all remained biochemically controlled with no clinical evidence of recurrent disease. The median PSA DT while on AS was 12 years. Twenty (62%) of the 32 patients on WW remained on observation, eight (25%) received palliative hormonal therapy and four (12%) died, including one from prostate cancer. AS is feasible in selected men with early prostate cancer. The natural history of this disease often appears extremely indolent, and most men on AS will avoid radical treatment. There is a marked contrast between AS (with radical treatment for biochemical progression) and WW (with palliative treatment for symptomatic progression). Ongoing studies are seeking to optimize the AS protocol, and to compare the long-term outcomes with those of immediate radical treatment.
Early outcomes of active surveillance for localized prostate cancer
  • C Hardie
  • C Parker
  • A Norman
  • R Eeles
  • A Horwich
  • R Huddart
  • D Deamaley
Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Deamaley D: Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005, 95:956-60.
EAU Guidelines on Disorders of Ejaculation
  • G Colpi
  • W Weidner
  • A Jungwirth
  • J Pomerol
  • G Papp
  • T Hargreave
  • G Dohle
Colpi G, Weidner W, Jungwirth A, Pomerol J, Papp G, Hargreave T, Dohle G: EAU Guidelines on Disorders of Ejaculation. European Urology 2004, 46:555-558.